Table Presentation

The incidence of clinical jaundice was 56%. The incidence of significant

hyperbilirubinemia (>17mg/dl) was 13% (Table I).

TABLE I: Incidence of Clinical Jaundice and significant

Hyperbilirubinemia.

Clinical Significant
Total
Jaundice Percentage Hyperbilirubinemia Percentage
enrollments
Present (≥17 mg/dl)

200 112 56 26 13
At 24±6hours as shown in Table II

a) TSB >6 mg/dl was present in 47 cases and 26 of these developed

hyperbilirubinemia (≥17 mg/dl).

b) TSB ≤6mg/dl was present in 153 cases and 2 of them developed

significant hyperbilirubinemia.

c) The sensitivity of TSB >6mg/dl at 24±6hrs in identifying those who will

develop hyperbilirubinemia was 92.86%. Specificity was 87.79%. The

positive predictive value was 55.31%. The negative predictive value was

98.69%. Therefore, the test is useful in identifying the infants who are

unlikely to develop hyperbilirubinemia.

TABLE II: Distribution of Hyperbilirubinemia cases

No. of cases No. of cases who

TSB at 24±6 hrs. who developed did not develop Total
TSB ≥17 mg/dl TSB≥17 mg/dl

>6 mg/dl 26 (a) 21 (b) 47

≤6 mg/dl 2 (c) 151 (d) 153

Total 28 172 200

Sensitivity: a /a+c 92.86%

Specificity: d/d+b 87.79%

Positive predictive value: a/a+b 55.31%

Negative predictive value: d/d+c 98.69%

 Table III below depicts:

a) The incidence of hyperbilirubinemia in Caesarean deliveries & vaginal

deliveries was 12.2% and 31.6% respectively with statistically significant

difference (χ2 (Chi-square) = 5.39, df = 1, P<0.05).

b) The mean values of TSB at 24±6hrs in Caesarean and vaginal deliveries

were 3.56±1.96 mg/dl and 4.57±2.59 mg/dl respectively with statistical

significant difference (t = 2.05, P<0.05).

c) The mean values of Peak TSB for Caesarean and vaginal deliveries were

12.32±3.66 mg/dl and 13.27±5.69 mg/dl respectively which was not

significant statistically (t = 1.01, P>0.05).

TABLE III: Compares the TSB at 24±6 hrs. and Peak TSB levels &
incidence of Hyperbilirubinemia amongst Caesarean and Vaginal
deliveries.

TSB at 24±6 hrs. Peak TSB level No. of babies No. of babies Total
Group
who developed who did not
TSB ≥17 mg/dl develop TSB
Range Mean SD Range Mean SD ≥17 mg/dl
181
Caesarean 1.0 – 9.2 3.56 1.97 2.4 – 24.0 12.32 3.66 22 (12.2%) 159 (87.8%)

19
Vaginal 0.8 – 8.6 4.57 2.59 2.30 -21.2 13.27 5.69 6(31.6%) 13(68.43%)

200
t = 2.05 P<0.05
t = 1.01, P>0.05 not χ2 (Chi-square) = 5.39, df = 1,
Significant
significant
P<0.05 significant.

Table IV below depicts:

a) The incidence of hyperbilirubinemia in babies whose mothers received

oxytocin and those whose mothers did not receive oxytocin was 19.6%

and 8.2% respectively. The difference was highly significant (χ2 (Chi-

square) = 5.44, df = 1, P<0.05).

 b) The mean values of TSB at 24±6hrs in oxytocin used and oxytocin not

used groups were 3.94±2.15 mg/dl and 3.36±1.91 mg/dl respectively. The

difference was statistically significant ('t' = 2.0, ‘P'<0.05)

c) The mean values of Peak TSB in oxytocin used and not used groups were

12.78±4.28 mg/dl and 12.03±3.42 mg/dl respectively which was

statistically not significant ('t' = 1.37 ‘P'>0.05).

Table IV: Compares the TSB at 24±6 hrs. and Peak TSB levels &

incidence of Hyperbilirubinemia oxytocin used and not used groups

TSB at 24±6 hrs. Peak TSB level No. of babies No. of babies Total
Group
who developed who did not
TSB ≥17 mg/dl develop TSB
Range Mean SD Range Mean SD ≥17 mg/dl
102
Oxytocin 20 (19.6%) 82 (80.4%)
0.8 – 9.2 3.94 2.15 2.3 – 24.0 12.78 4.28
used

98
Oxytocin not 8 (8.2%) 90 (91.8%)
1.0 – 8.3 3.36 1.91 2.4 – 21.9 12.03 3.42
used

't' = 2.01 'P'<0.05 't' = 1.37 ‘P'>0.05 Not χ2 (Chi-square) = 5.44, df = 1,

Significant 200
significant P<0.05 significant.